HC Wainwright Forecasts Strong Price Appreciation for Septerna (NASDAQ:SEPN) Stock

Septerna (NASDAQ:SEPN) had its price target increased by equities research analysts at HC Wainwright from $35.00 to $40.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 42.20% from the company’s current price.

Several other research firms have also weighed in on SEPN. Zacks Research raised shares of Septerna from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Truist Financial assumed coverage on shares of Septerna in a research report on Monday, December 15th. They issued a “buy” rating and a $34.00 price target on the stock. JonesTrading began coverage on shares of Septerna in a report on Tuesday, December 23rd. They set a “buy” rating and a $43.00 price objective for the company. Raymond James Financial began coverage on shares of Septerna in a research note on Friday, December 19th. They issued a “strong-buy” rating and a $38.00 target price for the company. Finally, Wells Fargo & Company upgraded Septerna from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $18.00 to $28.00 in a research report on Friday, November 14th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $38.00.

Septerna Price Performance

Shares of SEPN stock opened at $28.13 on Monday. The stock’s fifty day simple moving average is $26.93 and its 200 day simple moving average is $22.65. Septerna has a one year low of $4.66 and a one year high of $32.63. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of -18.63 and a beta of 3.46.

Insider Buying and Selling at Septerna

In other news, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total transaction of $115,880.00. Following the transaction, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $5,046,834.73. This represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. boosted its position in Septerna by 86.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after buying an additional 1,260,409 shares during the last quarter. First Light Asset Management LLC bought a new stake in shares of Septerna during the fourth quarter worth $17,308,000. Primecap Management Co. CA acquired a new position in shares of Septerna during the fourth quarter valued at $15,225,000. Perceptive Advisors LLC bought a new position in Septerna in the second quarter valued at about $5,723,000. Finally, VR Adviser LLC bought a new position in Septerna in the second quarter valued at about $5,713,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.